GYRE THERAPEUTICS, INC.(GYRE)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

GYRE THERAPEUTICS, INC. (GYRE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GYRE at 24.4/100 on a 32-signal composite quality model, placing it at rank #2,697 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (13.6) and profitability (14.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), GYRE THERAPEUTICS, INC. reports quarterly revenue of $29.1M, net income of $-14.3M, free cash flow of $-17.0M. Top institutional holders of GYRE by reported 13-F value include SC CHINA HOLDING Ltd, BlackRock, Octagon Capital Advisors, based on the most recent SEC filings. GYRE trades on the Nasdaq exchange and files with the SEC under CIK 1124105. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GYRE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GYRE THERAPEUTICS, INC. directly from SEC EDGAR.